Edwards Lifesciences Names New CFO Amid Leadership Transition
Event summary
- Theodora 'Doretta' Mistras appointed as Edwards Lifesciences' new CFO, effective end of May 2026.
- Mistras succeeds Scott Ullem, who announced his departure in October 2025.
- Mistras previously served as CFO at Viatris and held senior roles in healthcare investment banking at Citigroup and Goldman Sachs.
- Ullem served as CFO since 2014 and will continue as a strategic advisor during the transition.
The big picture
Edwards Lifesciences' appointment of Theodora Mistras as CFO underscores a strategic shift towards leveraging global finance expertise to drive innovation and durable financial results. The transition comes at a critical juncture for the company as it seeks to maintain its leadership position in the structural heart innovation space. Mistras' extensive experience in healthcare finance and investment banking suggests a focus on optimizing financial performance while navigating complex global markets.
What we're watching
- Strategic Alignment
- How Mistras' experience in global finance and healthcare investment banking will shape Edwards' strategy and financial planning.
- Execution Risk
- The pace at which Mistras can integrate into Edwards' culture and execute its differentiated strategy.
- Market Dynamics
- Whether Mistras' background will influence Edwards' approach to investor relations and long-term value creation.